Login to Your Account

LONDON – After failing to reach the primary endpoint in a 507-patient phase IIb trial in acute coronary syndrome (ACS), Cerenis Therapeutics SA has found a route forward for its CER-001 recombinant high-density lipoprotein (HDL), securing orphan drug status in two variants of an inherited rare disorder that causes HDL deficiency.
LONDON – After a "bake-off" between rival sequencing technologies, the UK government is announcing Friday a £78 million (US$132 million) contract with Illumina Inc. to deliver the equipment and services for its 100,000 Genomes Project.
All of the UK's public research funding agencies, from arts and humanities to engineering and physical sciences, are uniting in a "war cabinet" to tackle antimicrobial resistance (AMR) in a coordinated fashion across all fronts, from drug discovery to monitoring resistant microbes in the environment and influencing behavior to prevent and control infections.
More EUROPE Headlines

Cast Your Vote

Has biotech’s bubble burst?: